TY - JOUR
T1 - Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy
AU - Dhawale, Tejaswini M.
AU - Johnson, P. Connor
AU - Gaballa, Mahmoud R.
AU - Nelson, Ashley M.
AU - Lavoie, Mitchell W.
AU - Boateng, Kofi Y.
AU - Greydanus, Claire
AU - Frigault, Matthew J.
AU - El-Jawahri, Areej
N1 - Funding Information:
Tejaswini M. Dhawale reports grant funding from the American Cancer Society. Areej El‐Jawahri reports consulting fees from GlaxoSmithKline, Incyte, and Novartis, and stock in ElevateTherapeutics. Matthew J. Frigault reports consulting fees from Bristol‐Myers Squibb, Iovance, Kite Pharma, Johnson & Johnson/Legend, and Novartis. P. Connor Johnson reports consulting fees from ADC Therapeutics, AstraZeneca, Medically Home, and Seagen Inc. Ashley M. Nelson reports grant funding from National Heart, Lung, and Blood Institute.
Funding Information:
Areej El‐Jawahri is a Scholar in Clinical Research for the Leukemia and Lymphoma Society. This study was supported by the Leukemia and Lymphoma Society.
Publisher Copyright:
© 2022 American Cancer Society.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Background: Chimeric antigen receptor (CAR) T-cell is potentially curative therapy for patients with hematologic malignancies but can cause life-threatening toxicities. Data on perceptions of prognosis and psychological distress are lacking. Methods: The authors conducted a cross-sectional study of patients receiving CAR-T. Before hospitalization for CAR-T, patients completed assessments of quality of life (QOL) (Functional Assessment of Cancer Therapy-General), anxiety and depression symptoms (Hospital Anxiety and Depression Scale) and post-traumatic stress disorder symptoms (Post-Traumatic Stress Checklist). Patients also completed the Prognostic Awareness Impact Scale (PAIS), which measures three domains: cognitive understanding of prognosis, emotional coping with prognosis, and adaptive response. Results: A total of 71.8% (102 of 142) of eligible patients were enrolled. A total of 34% of patients reported that their oncologist said their cancer is curable and 64% reported there was >50% chance of cure. Overall, 26%, 30%, and 21% of patients reported clinically significant depression, anxiety, and posttraumatic stress disorder (PTSD) symptoms, respectively. We found no association between patients' cognitive understanding of prognosis and QOL or mood. Higher emotional coping with prognosis was associated with better QOL (Β = 0.72; SE = 0.10; p = <.001) and lower depression (Β = −0.17; SE = 0.02; p = <.001), anxiety (Β = −0.21; SE = 0.02; p = <.001), and PTSD (Β = −0.43; SE = 0.06; p = <.001) symptoms. Higher adaptive response was associated with better QOL (Β = 0.19; SE = 0.09; p =.028) and lower depression (Β = −0.05; SE = 0.02; p =.023), anxiety (Β = −0.09; SE = 0.02; p = <.001), and PTSD (Β = −0.19; SE = 0.05; p = <.001) symptoms. Conclusions: Patients undergoing CAR-T report overly optimistic perception of their prognosis and have high rates of psychological distress. Higher emotional coping with prognosis and adaptive response were associated with better QOL and less psychological distress, underscoring the need to develop interventions to promote coping with this treatment. Plain language summary: Patients undergoing chimeric antigen receptor T-cell therapy experience report overly optimistic perceptions of their prognosis and have high rates of psychological distress. Notably, higher emotional coping with prognosis and adaptive response were associated with better quality of life and less psychological distress.
AB - Background: Chimeric antigen receptor (CAR) T-cell is potentially curative therapy for patients with hematologic malignancies but can cause life-threatening toxicities. Data on perceptions of prognosis and psychological distress are lacking. Methods: The authors conducted a cross-sectional study of patients receiving CAR-T. Before hospitalization for CAR-T, patients completed assessments of quality of life (QOL) (Functional Assessment of Cancer Therapy-General), anxiety and depression symptoms (Hospital Anxiety and Depression Scale) and post-traumatic stress disorder symptoms (Post-Traumatic Stress Checklist). Patients also completed the Prognostic Awareness Impact Scale (PAIS), which measures three domains: cognitive understanding of prognosis, emotional coping with prognosis, and adaptive response. Results: A total of 71.8% (102 of 142) of eligible patients were enrolled. A total of 34% of patients reported that their oncologist said their cancer is curable and 64% reported there was >50% chance of cure. Overall, 26%, 30%, and 21% of patients reported clinically significant depression, anxiety, and posttraumatic stress disorder (PTSD) symptoms, respectively. We found no association between patients' cognitive understanding of prognosis and QOL or mood. Higher emotional coping with prognosis was associated with better QOL (Β = 0.72; SE = 0.10; p = <.001) and lower depression (Β = −0.17; SE = 0.02; p = <.001), anxiety (Β = −0.21; SE = 0.02; p = <.001), and PTSD (Β = −0.43; SE = 0.06; p = <.001) symptoms. Higher adaptive response was associated with better QOL (Β = 0.19; SE = 0.09; p =.028) and lower depression (Β = −0.05; SE = 0.02; p =.023), anxiety (Β = −0.09; SE = 0.02; p = <.001), and PTSD (Β = −0.19; SE = 0.05; p = <.001) symptoms. Conclusions: Patients undergoing CAR-T report overly optimistic perception of their prognosis and have high rates of psychological distress. Higher emotional coping with prognosis and adaptive response were associated with better QOL and less psychological distress, underscoring the need to develop interventions to promote coping with this treatment. Plain language summary: Patients undergoing chimeric antigen receptor T-cell therapy experience report overly optimistic perceptions of their prognosis and have high rates of psychological distress. Notably, higher emotional coping with prognosis and adaptive response were associated with better quality of life and less psychological distress.
KW - advanced cancer
KW - chimeric antigen receptor T-cell therapy
KW - distress
KW - prognostic awareness
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85143394961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143394961&partnerID=8YFLogxK
U2 - 10.1002/cncr.34557
DO - 10.1002/cncr.34557
M3 - Article
C2 - 36457279
AN - SCOPUS:85143394961
SN - 0008-543X
VL - 129
SP - 441
EP - 449
JO - Cancer
JF - Cancer
IS - 3
ER -